These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 4007040)

  • 21. A double-blind, randomized, controlled trial comparing pinacidil to hydralazine in essential hypertension.
    Byyny RL; Nies AS; LoVerde ME; Mitchell WD
    Clin Pharmacol Ther; 1987 Jul; 42(1):50-7. PubMed ID: 3297468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of long term treatment with pinacidil and nifedipine on left ventricular anatomy and function in patients with mild to moderate systemic hypertension.
    Steensgaard-Hansen F; Carlsen JE
    Drugs; 1988; 36 Suppl 7():70-6. PubMed ID: 3254831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular effects of pinacidil and propranolol alone and in combination in normal humans.
    Nicholls DP; McNeill J; Harron DW; Shanks RG
    J Cardiovasc Pharmacol; 1986; 8(1):51-4. PubMed ID: 2419692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension.
    Izzo JL; Licht MR; Smith RJ; Larrabee PS; Radke KJ; Kallay MC
    Am J Cardiol; 1987 Aug; 60(4):303-8. PubMed ID: 2887102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension.
    Solomon RJ; Weinberg MS
    J Clin Hypertens; 1987 Dec; 3(4):589-95. PubMed ID: 3330989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immediate central and peripheral haemodynamic effects of a new vasodilating agent Pinacidil (P1134) in hypertensive man.
    Carlsen JE; Kardel T; Hilden T; Tangø M; Trap-Jensen J
    Clin Physiol; 1981 Aug; 1(4):375-84. PubMed ID: 7199409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.
    Ward JW; McBurney A; Farrow PR; Sharp P
    Eur J Clin Pharmacol; 1984; 26(5):603-8. PubMed ID: 6468476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of pinacidil on serum lipid, lipoprotein, and apolipoprotein levels in patients with mild to moderate hypertension.
    Saku K; Ying H; Arakawa K
    Clin Ther; 1990; 12(2):132-8. PubMed ID: 2354482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A postmarketing evaluation of guanfacine hydrochloride in mild to moderate hypertension.
    Board AW; Perry VP; Shepperson BE; Nyman CE; Carchman SH
    Clin Ther; 1988; 10(6):761-75. PubMed ID: 3064907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute hemodynamic effects of pinacidil and hydralazine in essential hypertension.
    Carlsen JE; Kardel T; Lund JO; McNair A; Trap-Jensen J
    Clin Pharmacol Ther; 1985 Mar; 37(3):253-9. PubMed ID: 2857601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous pinacidil in the acute treatment of hypertension.
    Rijk MC; Thien T
    J Clin Pharmacol; 1987 Jul; 27(7):468-74. PubMed ID: 3308975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels.
    Goldberg MR
    J Cardiovasc Pharmacol; 1988; 12 Suppl 2():S41-7. PubMed ID: 2466178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid and apolipoprotein levels during therapy with pinacidil combined with hydrochlorothiazide.
    Corder CN; Goldberg MR; Alaupovic PA; Price MD; Furste SS
    Eur J Clin Pharmacol; 1992; 42(1):65-70. PubMed ID: 1541318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical evaluation of the vasodilator MDL-899 in patients with essential hypertension.
    Elliott HL; Campbell L; Sumner DJ; Reid JL
    J Cardiovasc Pharmacol; 1985; 7(5):948-52. PubMed ID: 2413306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A Brazilian multicenter study to evaluate the clinical effectiveness and tolerance of isradipine SRO using ambulatory monitoring of arterial pressure in the treatment of mild and moderate arterial hypertension].
    Magliano MF; Amodeo C; Mion Júnior D; Francischetti E; Lima Júnior E; Nobre F; Chaves H; Ribeiro JM; Spritzer N; Jardim PC
    Arq Bras Cardiol; 1993 Nov; 61(5):311-8. PubMed ID: 8147731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and bioavailability of pinacidil capsules in human volunteers.
    Laher MS; Hickey MP
    J Int Med Res; 1985; 13(3):159-62. PubMed ID: 4007251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of long-acting pinacidil on intra-arterial blood pressure.
    Caruana MP; Al-Khawaja I; Royston P; Raftery EB
    Br J Clin Pharmacol; 1985 Aug; 20(2):140-3. PubMed ID: 4041331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prizidilol (SK & F 92657), a new vasodilator with beta-blocking properties in the treatment of essential hypertension.
    Lüscher T; Havelka J; Greminger P; Tuma J; Täuber M; Siegenthaler W; Vetter W
    Eur J Clin Pharmacol; 1982; 23(5):411-5. PubMed ID: 6129980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal effects of pinacidil in hypertensive patients on chronic beta-blocker therapy.
    Krusell LR; Christensen CK; Lederballe Pedersen O
    Eur J Clin Pharmacol; 1986; 30(6):641-7. PubMed ID: 2876898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of guanfacine versus clonidine for efficacy, safety and occurrence of withdrawal syndrome in step-2 treatment of mild to moderate essential hypertension.
    Wilson MF; Haring O; Lewin A; Bedsole G; Stepansky W; Fillingim J; Hall D; Roginsky M; McMahon FG; Jagger P
    Am J Cardiol; 1986 Mar; 57(9):43E-49E. PubMed ID: 3513530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.